Medical Advocates
Cytomegalovirus Infection/Disease
  Drugs
 
General Reports
ARVs: General
Acyclovir
 Alemtuzumab
Corticosteroids
Cidofovir 
 Cytogam 
FK 506
 Fomivirsen   
 Foscarnet 
Ganciclovir
Immunoglobulin		 Leflunomide
Maribavir
Sirolimus:
Valganciclovir
Voriconazole





 
CMV Main Page   Main New / Noteworthy Home Page 
Last Update:  September 03, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
                
     Journal Papers, Abstracts, and Commentaries
 
 
Management of cytomegalovirus infections in patients treated with immunosuppressive drugs
for chronic inflammatory diseases.
Tnani N, Massoumi A, Lortholary O, et al
Rev Med Interne. 2007 Oct 31
 Abstract

Immunoglobulins, vaccines or interferon for preventing cytomegalovirus disease in
solid organ transplant recipients.
Hodson E, Jones C, Strippoli G,et al
Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005129.
 Abstract
Antivirals: General
                
     Journal Papers, Abstracts, and Commentaries
 
 
Cytomegalovirus retinitis and immune recovery uveitis in AIDS patients treated with highly active antiretroviral
therapy in Taiwanese.
Lin YC, Yang CH, Lin CP,  et al
Ocul Immunol Inflamm. 2008 May-Jun;16(3):83-7.
 Abstract
 
Antiretroviral therapy in AIDS patients with CMV disease: Impact on the survival and long-term
treatment outcome.
Sungkanuparph S, Chakriyanuyok T, Butthum B.
J Infect. 2007 Nov 21
 Abstract
 
Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ
transplant recipients.
Cochrane AB. 
Am J Health Syst Pharm. 2006 Oct 1;63(19 Suppl
Abstract
 
Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive
therapy.
Singh N.   
Rev Med Virol. 2006 Sep-Oct;16(5):281-7.
Abstract

Incidence and Prognosis of CMV Disease in HIV-Infected Patients before and after
Introduction of Combination Antiretroviral Therapy.
Salzberger B, Hartmann P, Hanses F, et al 
Infection. 2005 Oct;33(5-6):345-9.
 Abstract
Acyclovir
                
     Journal Papers, Abstracts, and Commentaries
 
  Effect of cytomegalovirus prophylaxis with acyclovir on renal transplant survival.
Abraham KA, O'Kelly P, Spencer S, et al
 en Fail. 2008;30(2):141-6.
 Abstract
Alemtuzumab
                
     Journal Papers, Abstracts, and Commentaries
 
 
Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem
cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations
in the UL97 and UL54 genes.
Oshima K, Kanda Y, Kako S, et al  
J Med Virol. 2008 Oct;80(10):1769-75.
 Abstract

Impact of alemtuzumab as conditioning regimen component on transplantation outcomes in case of
CMV-seropositive recipients and donors.
Chae YS, Sohn SK, Kim JG, et al  Am J Hematol. 2008 May 9.
Abstract
Cidofovir
                

     Journal Papers, Abstracts, and Commentaries

 
Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in
treatment of DNA virus and retrovirus infections.
De Clercq E.|
Clin Microbiol Rev. 2003 Oct; 16(4): 569-96.
 Abstract
 
Bilateral uveitis with definitive hypotony caused by systemic cidofovir
Rapp P, Pilon F, Chiambaretta F, et al 
J Fr Ophtalmol. 2003 Sep;26(7):717-9.
 Abstract

Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-
infected patients with cytomegalovirus retinitis.
Wolf DL, Rodriguez CA, Mucci M, et al.
J Clin Pharmacol 2003 Jan;43(1):43-51
 Abstract

  
Corticosteroids
                
     Journal Papers, Abstracts, and Commentaries
 
  Fatal cytomegalovirus-associated adrenal insufficiency in an AIDS patient receiving
corticosteroid therapy.
Uno K, Konishi M, Yoshimoto E, et al 
Intern Med. 2007;46(9):617-20.
 Abstract
Cytogam
                
     Journal Papers, Abstracts, and Commentaries
 
  Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-
seropositive lung transplant recipients.
Kruger RM, Paranjothi S, Storch GA
J Heart Lung Transplant. 2003 Jul;22(7):754-63.
Abstract
FK 506
                
     Journal Papers, Abstracts, and Commentaries
 
  Cytomegalovirus retinitis and FK 506.
Ciardella AP, Barile G, Langton K, Chang S.
Am J Ophthalmol. 2003 Aug;136(2):386-9.
Abstract
Fomivirsen  
                

     Journal Papers, Abstracts, and Commentaries

  A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly
diagnosed peripheral cytomegalovirus retinitis in patients with AIDS
[No authors listed].
Am J Ophthalmol 2002  Apr;133(4):467-474
 Abstract
   
  Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients
with AIDS
[No authors listed]
Am J Ophthalmol 2002 Apr;133(4):484-498
 Abstract
   
  Randomized dose-comparison studies of intravitreous fomivirsen for treatment of
cytomegalovirus retinitis that has reactivated or is persistently active despite other
herapies in patients with AIDS
Am J Ophthalmol 2002 Apr;133(4):475-483
 Abstract
   
  Inhibition of human cytomegalovirus replication in a human retinal epithelial cell model by
antisense oligonucleotides.
Detrick B, Nagineni CN, Grillone LR, et al.
Invest Ophthalmol Vis Sci 2001 Jan;42(1):163-9
 Abstract
   
  Reversible bull's-eye maculopathy associated with intravitreal fomivirsen therapy for
cytomegalovirus retinitis.
Stone TW, Jaffe GJ.
Am J Ophthalmol 2000 Aug;130(2):242-3
 Abstract
Foscarnet
                

     Journal Papers, Abstracts, and Commentaries

 
Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with
possible dual-strain cytomegalovirus coinfection.
Rodriguez J, Casper K, Smallwood G, et al
Liver Transpl. 2007 Oct;13(10):1396-400.
 Abstract
 
Reduced dose of foscarnet as preemptive therapy for cytomegalovirus infection following
reduced-intensity cord blood transplantation.
Narimatsu H, Kami M, Kato D, et al 
Transpl Infect Dis. 2007 Mar;9(1):11-5.
 Abstract

Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of
cytomegalovirus infection after allogeneic stem cell transplantation
Reusser P, Einsele H, Lee J, et al.
Blood 2002 Feb 15;99(4):1159-64
 Abstract
Ganciclovir
                

     Journal Papers, Abstracts, and Commentaries                    

 
Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation.
Valentine VG, Weill D, Gupta MR, et al 
J Heart Lung Transplant. 2008 Aug;27(8):875-81
 Abstract
 
Preemptive therapy with ganciclovir 5 mg/kg once daily for cytomegalovirus infection after
unrelated cord blood transplantation.
Tomonari A, Takahashi S, Ooi J, et al 
Bone Marrow Transplant. 2007 Nov 5;
 Abstract
 
Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with
possible dual-strain cytomegalovirus coinfection.
Rodriguez J, Casper K, Smallwood G, et al
Liver Transpl. 2007 Oct;13(10):1396-400.
 Abstract
 
Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation.
West P, Schmiedeskamp M, Neeley H, et al
Transpl Infect Dis. 2007 Jul 1;
 Abstract
 
Safety and efficacy of prolonged cytomegalovirus prophylaxis with intravenous ganciclovir in
pediatric and young adult lung transplant recipients.
Spivey JF, Singleton D, Sweet S, et al 
Pediatr Transplant. 2007 May;11(3):312-8.
Abstract
 
Change over time in incidence of ganciclovir resistance in patients with cytomegalovirus
retinitis.
Martin BK, Ricks MO, Forman MS, et al 
Clin Infect Dis. 2007 Apr 1;44(7):1001-8.
 Abstract
 
Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease
in recipients of kidney and pancreas transplants.
Weng FL, Patel AM, Wanchoo R, et al   
Transplantation. 2007 Feb 15;83(3):290-6.
Abstract
 
A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus
(CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
Shereck EB, Cooney E, van de Ven C, et al 
Pediatr Blood Cancer. 2006 Sep 13;
Abstract
 
Detection of ganciclovir resistance in patients with AIDS and cytomegalovirus retinitis:
correlation of genotypic methods with viral phenotype and clinical outcome.
Jabs DA, Martin BK, Ricks MO,   
J Infect Dis. 2006 Jun 15;193(12):1728-37.
Abstract

Outcomes associated with ganciclovir implants in patients with AIDS-related
cytomegalovirus retinitis.
Kappel PJ, Charonis AC, Holland GN, et al 
Ophthalmology. 2006 Apr;113(4):683.e1-8.
Abstract

A randomized trial of ganciclovir versus ganciclovir plus immune globulin for prophylaxis
against Epstein-Barr virus related posttransplant lymphoproliferative disorder.
Humar A, Hebert D, Davies HD, Humar A, .et al
Transplantation. 2006 Mar 27;81(6):856-61.
Abstract
 
Influence of ganciclovir prophylaxis on cyitomegalovirus, human herpesvirus 6, and
human herpesvirus 7 viremia in renal transplant recipients.
Galarraga MC, Gomez E, de Ona M ,et al 
Transplant Proc. 2005 Jun;37(5):2124-6.
Abstract
 
Following Universal Prophylaxis with Intravenous Ganciclovir and Cytomegalovirus Immune
Globulin, Valganciclovir is Safe and Effective for Prevention of CMV Infection Following Lung
Transplantation.
Zamora MR, Nicolls MR, Hodges TN 
Am J Transplant. 2004 Oct;4(10):1635-42
 Abstract
 
Cytomegalovirus UL97 mutations associated with ganciclovir resistance in
 immunocompromised patients from Argentina.
Sanchez Puch S, Ochoa C, et al  
J Clin Virol. 2004 Jul;30(3):271-5.
 Abstract 
 
Emergence of drug-resistant cytomegalovirus retinitis in the contralateral eyes of
patients with AIDS treated with ganciclovir.
Imai Y, Shum C, Martin DF, et al
J Infect Dis. 2004 Feb 15;189(4):611-5
 Abstract 
 
Efficacy preemptive therapy with ganciclovir for the prevention of cytomegalovirus disease
in liver transplant recipients
Lopez-Medrano F, Lumbreras C, Otero JR, et al 
Med Clin (Barc). 2004 Jan 24; 122(2): 41-5.
Abstract   
 
Endophthalmitis after ganciclovir implant in patients with AIDS and cytomegalovirus
retinitis.
Shane TS, Martin DF; Endopthalmitis-Gancioclovir Implant Study Group.
Am J Ophthalmol. 2003 Oct; 136(4): 649-54.
 Abstract   

Intravitreal sustained-release ganciclovir implants for severe bilateral cytomegalovirus
retinitis after stem cell transplantation.
Ghosh F, Hansson LJ, Bynke G, Bekassy AN.  
Acta Ophthalmol Scand 2002 Feb;80(1):101-4 
Abstract   

   
  Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of
cytomegalovirus infection after allogeneic stem cell transplantation
Reusser P, Einsele H, Lee J, et al.
Blood 2002 Feb 15;99(4):1159-64
 Abstract
   
  Response-oriented preemptive therapy against cytomegalovirus disease with low-dose
ganciclovir: a prospective evaluation.
Kanda Y, Mineishi S, Saito T,  et al.
Transplantation 2002 Feb 27;73(4):568-72
 Abstract 
 
Treatment of CMV retinitis with intravitral ganciclovir in the HAART era.
Campbell RJ, Chow B, Victor G,et al
Can J Infect Dis. 2001 Sep;12(5):300-4.
 Abstract
Immunoglobulin
                

     Journal Papers, Abstracts, and Commentaries

  Cytomegalovirus prophylaxis with intravenous polyvalent immunoglobulin in high-risk renal
transplant recipients.
Leroy F, Sechet A, Abou Ayache R, et al 
Transplant Proc. 2006 Sep;38(7):2324-6.
 Abstract
Leflunomide
                

     Journal Papers, Abstracts, and Commentaries

  Leflunomide: a possible alternative for gangciclovir sensitive and resistant cytomegalovirus
infections.
Sudarsanam TD, Sahni RD, John GT. et al 
Postgrad Med J. 2006 May;82(967):313-4.
 Abstract
Maribavir
                

     Journal Papers, Abstracts, and Commentaries

 
Maribavir: A Novel Antiviral Agent with Activity Against Cytomegalovirus.
Trofe J, Pote L, Wade E, et al
Ann Pharmacother. 2008 Aug 12.
 Abstract

Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem-cell
transplant recipients: a multicenter, randomized, double-blind, placebo-controlled,
dose-ranging study.
Winston DJ, Young JA, Pullarkat V, et al
Blood. 2008 Feb 19
Abstract
Sirolimus:
                

     Journal Papers, Abstracts, and Commentaries

  Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with
sirolimus: a pooled analysis of clinical trials.
Demopoulos L, Polinsky M, Steele G, et al  Transplant Proc. 2008 Jun;40(5):1407-10.
 Abstract
Valganciclovir
                
     Journal Papers, Abstracts, and Commentaries
 
 
Selective low-dose valganciclovir for prevention of cytomegalovirus disease following kidney transplantation
Avidan YP, Paul M, Rahamimov R, et al 
J Infect. 2008 Jul 30.
 Abstract
 
Prophylactic and pre-emptive therapy for cytomegalovirus infection in kidney transplant patients using
oral valganciclovir.
Guirado L, Rabella N, Díaz JM, et al  
Nefrologia. 2008;28(3):293-300.
 Abstract
 
High incidence of cytomegalovirus disease in D+/R- heart transplant recipients shortly after
completion of 3 months of  valganciclovir prophylaxis.
Gupta S, Mitchell JD, Markham DW, et al
J Heart Lung Transplant. 2008 May;27(5):536-9.
Abstract
 
Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis:
therapeutic implications and outcomes.
Eid AJ, Arthurs SK, Deziel PJ, et al 
Clin Transplant. 2008 Mar-Apr;22(2):162-70.
 Abstract
 
Valganciclovir prevents CMV reactivation in patients receiving alemtuzumab based therapy.
O'Brien S, Ravandi F, Riehl T, et al
Blood. 2007 Nov 26; [
 Abstract
 
Valacyclovir Prophylaxis Versus Preemptive Valganciclovir Therapy to Prevent
Cytomegalovirus Disease After Renal Transplantation.
Reischig T, Jindra P, Hes O, et al
Am J Transplant. 2007 Oct 31;
Abstract
 
Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus
disease in high-risk solid organ transplant recipients.
Cervera C, Pineda M, Linares L, et al
Transplant Proc. 2007 Sep;39(7):2228-30.
 Abstract
 
Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease
in recipients of kidney and pancreas transplants.
Weng FL, Patel AM, Wanchoo R, et al   
Transplantation. 2007 Feb 15;83(3):290-6.
Abstract
 
Successful treatment with oral valganciclovir in immunocompetent infant with
gastrointestinal manifestations of cytomegalovirus infection.
Buonuomo PS, Maurizi P, Valentini P, et al  
J Perinatol. 2006 Oct;26(10):648-649.
 Abstract
 
Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk
seropositive solid-organ transplant recipients.
Diaz-Pedroche C, Lumbreras C, San Juan R, et al  
Transplantation. 2006 Jul 15;82(1):30-5.
 Abstract
 
Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA
load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.
van der Heiden PL, Kalpoe JS, Barge RM,    et al  
Bone Marrow Transplant. 2006 Apr;37(7):693-8.
 Abstract
 
Treatment of cytomegalovirus retinitis with oral valganciclovir in an acquired immunodeficiency
syndrome patient unresponsive to combination antiretroviral therapy.
Lee CH, Bright DC, Ferrucci S, .et al   
Optometry. 2006 Apr;77(4):167-76.
 Abstract
 
Following Universal Prophylaxis with Intravenous Ganciclovir and Cytomegalovirus
Immune Globulin, Valganciclovir is Safe and Effective for Prevention of CMV Infection
Following Lung Transplantation.
Zamora MR, Nicolls MR, Hodges TN 
Am J Transplant. 2004 Oct;4(10):1635-42
 Abstract
 
Valganciclovir: new preparation; CMV retinitis: a simpler oral treatment.
{no authors listed]
Prescrire Int. 2003 Aug;12(66)
 Abstract

A safety study of oral valganciclovir maintenance treatment ofcytomegalovirus retinitis.
Lalezari J, Lindley J, Walmsley S, et al.
J Acquir Immune Defic Syndr 2002 Aug 1;30(4):392-400
 Abstract

Valganciclovir: an advance in cytomegalovirus therapeutics.
 Cocohoba JM, McNicholl IR.
Ann Pharmacother 2002 Jun;36(6):1075-9
 Abstract

A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis..
Martin DF, Sierra-Madero J, Walmsley S, et al 
N Engl J Med 2002 Apr 11;346(15):1119-26
 Abstract

Oral valganciclovir: a new option for treatment of cytomegalovirusinfection and disease
in immunocompromised hosts.
Reusser P
 Expert Opin Investig Drugs 2001 Sep;10(9):1745-53
 Abstract

Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with
acquired immunodeficiency syndrome who are receiving valganciclovir as induction and
maintenance therapy for CMV retinitis.
Boivin G, Gilbert C, Gaudreau A, et al.
J Infect Dis 2001 Dec 15;184(12):1598-602
 Abstract    
                              
Valganciclovir.
 Curran M, Noble S.
 Drugs 2001;61(8):1145-50 ; discussion 1151-2
 Abstract    
 
     Conference Reports, Abstracts, and Posters
 
  Randomized, Placebo Controlled Trial of Valganciclovir to Prevent CMV End-organ
Disease among HIV-infected Subjects with Detectable Plasma CMV DNA PCR:
ACTG 5030
D Wohl, M Kendall, J Andersen, et al
(13 CROI)
 Abstract
Voriconazole
                
     Journal Papers, Abstracts, and Commentaries
 
  Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia i
n non-neutropenic patients: a randomised non-inferiority trial.
Kullberg BJ, Sobel JD, Ruhnke M   
Lancet. 2005 Oct 22-28;366(9495):1435-42.
Abstract

CMV Main Page   Main New / Noteworthy Home Page 

CMV Infection Drugs